Gastroenterology
Neoadjuvant Immunotherapy in dMMR Colon Cancer: A Breakthrough in Survival Outcomes
The NICHE-2 trial demonstrates that neoadjuvant immunotherapy with ipilimumab and nivolumab yields 100% three-year disease-free and five-year overall survival in mismatch repair-deficient colon cancer patients, marking a potential new stand
